Clinical guidelines recommend using Kidney Disease Improving Global Outcomes (KDIGO) criteria for the diagnosis and classification of acute kidney injury (AKI) in patients with chronic liver disease (CLD). Concerns have been raised about the use of urine output (UO) criteria in CLD. We examined the significance of oliguria meeting the urine output criteria for AKI (AKI-UO) and examined its association with clinical outcomes in CLD patients. Using an 8-year clinical database from a large university medical center, 3458 patients with CLD were identified. AKI occurred in 2854 (82.5%) patients when they fulfilled any KDIGO criteria. When serum creatinine (SC) and UO criteria were used, 604 patients (17.5%) had no evidence of AKI and had the lowest hospital mortality rate (5%). Using AKI-UO criteria alone, 2103 patients (60.8%) were classified as stage 2-3 AKI. When only SC criteria were applied, 1281 (61%) of those patients with stage 2-3 AKI-UO were misclassified as either no AKI or AKI stage 1. Patients reclassified with AKI according to UO criteria (AKI-UO) had nearly a 3-fold increased rate of hospital mortality compared with patients without any AKI (14.6% versus 5%; P < 0.001) and more than a 50% increased mortality compared with stage 1 AKI-SC (14.6% versus 9%; P < 0.001). Patients with transient oliguria (AKI-UO stage 1) had increased mortality rates compared with patients without oliguria (14.9% versus 6.9%; P < 0.001). Conclusion: CLD patients have a high incidence of AKI. Compared with creatinine criteria alone, incorporating UO into the diagnostic criteria increased the measured incidence of AKI. Stage 2-3 AKI-UO has a high negative impact on hospital mortality. (HEPATOLOGY 2017;66:1592-1600 
A cute kidney injury (AKI) is a common complication in patients with chronic liver disease (CLD) and especially those with cirrhosis. The incidence of AKI varies from 20% to 60% of hospitalized patients with cirrhosis depending on the definition used.
(1-4) AKI exerts a negative impact on the clinical course of the liver disease. Moreover, hospital mortality is directly correlated with the severity of AKI. (1, 5) According to Kidney Disease Improving Global Outcomes (KDIGO), AKI is defined by either an increase in serum creatinine (SC), a decrease in urine output (UO), or both (6) (Table 1) . However, the UO criteria of AKI definition is often discarded because of difficulties in making consistent measurements, and the frequent use of diuretics in patients with CLD affects UO interpretation. In fact, the revised consensus of the International Ascites Club recommended using only the SC component of the KDIGO criteria for the diagnosis and classification of AKI in patients with liver cirrhosis. (7) Glomerular filtration rate may decrease before an increase in SC is detected. This is even more pronounced in patients with cirrhosis who have compromised hepatic conversion of creatinine, lower muscle mass, and increased renal tubular secretion of creatinine. (8, 9) Although oliguria is frequent in patients with CLD who are admitted to the intensive care unit (ICU), UO has not been used in the diagnosis and staging for AKI. In this study, we sought to examine the significance of oliguria meeting the UO criteria of AKI (AKI-UO) and examine the relationship between AKI stage and clinical outcomes in patients with CLD.
Material and Methods

SOURCE POPULATION
We conducted a retrospective cohort study using the High-Density Intensive Care (HiDenIC-8) database that included 45,568 adult patients admitted to one of eight ICUs (medical, cardiac, transplant, surgical, neurological, and trauma) within a university medical center (University of Pittsburgh Medical Center: University of Pittsburgh Medical Center PresbyterianMontefiore, Pittsburgh, PA) during an 8-year period (July 2000 through October 2008). HiDenIC-8 data were obtained from several computerized databases and subsequently deidentified using an honest broker as described previously. (10) For the current analysis, we applied the following exclusion criteria: 1) history of chronic dialysis and/or renal transplantation (n 5 3600), 2) known baseline creatinine > 3.5 mg/dL (n 5 147), 3) no history of or inability to confirm the diagnosis of CLD (n 5 37,435), and 4) SC and UO measurements either unavailable or inadequate for AKI staging (n 5 928). The remaining 3458 patients with CLD formed our study population. Figure 1 represents the study flow chart. We obtained approval for the study from the University of Pittsburgh Institutional Review Board.
DATA COLLECTION
The diagnosis of CLD was made based on codes corresponding to the disease (e.g., chronic liver disease and cirrhosis, chronic viral hepatitis) and complications of CLD (e.g., varices, ascites, alcoholic hepatitis, encephalopathy) using the International Classification of Diseases, Ninth Revision (ICD-9). Demographic data consisted of age, sex, race, and body mass index. Severity scores included acute physiology score (APS-III) and severity of hypotension. Admission type (medical versus surgical) was based on the diagnosis related group at hospital admission. Comorbid conditions and etiologies of liver disease were determined by ICD-9 codes. Serum albumin, total serum bilirubin, international normalized ratio, Model for End-Stage Liver Disease (MELD) score, estimated glomerular filtration rate, suspected sepsis, fluids infused, use of vasopressors, mechanical ventilation support, and use of nephrotoxic drugs were also considered. All variables were measured within the first 24 hours of ICU admission as described previously. (10) Baseline creatinine was defined as the lowest value of 1) the most recent prehospital creatinine within 1 year of the index hospital admission and 2) the admission creatinine recorded in the first 24 hours of index hospital admission. Reference creatinine was the baseline creatinine when available, otherwise the lowest value between 1) admission creatinine, 2) creatinine in the first 24 hours of ICU admission, and 3) (for patients without history of CKD) creatinine derived from the Modification of Diet in Renal Disease equation using a glomerular filtration rate of 75 mL/min per 1.73 m 2 . (11) (12) (13) Development of AKI was evaluated during the first 7 days of the ICU admission where AKI was defined as any of following criteria: increase in SC (AKI-SC) by 0.3 mg/dL within 48 hours; or increase in SC to 1.5 times reference creatinine or urine volume (AKI-UO) < 0.5 mL/kg/h for 6 hours. When AKI was present, we classified patients into three stages based on the maximum KDIGO criteria met in the first 7 days after ICU admission using SC and UO criteria. (6) Persistent oliguria was defined as stage 2 or 3 according to UO criteria (<0.5 mL/kg/h for more than 12 hours and <0.3 mL/kg/h for more than 24 hours or anuria for more than 12 hours, respectively) and transient oliguria was defined as stage 1 according to UO criteria (<0.5 mL/kg/h during 6 hours). AKI-SC1UO implied that patients fulfilled both SC and UO criteria of AKI. Because renal replacement therapy (RRT) was used as an outcome, we did not apply it as a staging criterion for participants that were started on RRT before achieving stage 3 criteria by UO or SC. Complications related to portal hypertension were defined by presence of varices (with or without bleeding) and/or presence of ascites. Patients with past medical history of ascites and varices bleeding were considered to have significant portal hypertension.
OUTCOME ASSESSMENT
Our primary outcomes were initiation of RRT, in hospital mortality rate, and 1-year mortality rate. Chronic RRT was defined by the entrance date into the United States Renal Data System. Mortality at 1 year was determined from the National Death Index database or the Social Security Administration Death Master File.
STATISTICAL ANALYSIS
Statistical analyses were performed using the STATA software, version SE 11.2, with statistical significance set at P < 0.05. Comparisons between groups were performed with Pearson's chi-square asymptotic test for categorical variables and using Kruskal-Wallis one-way analysis of variance by ranks for continuous variables. Survival graphs were created using the R "survival" package (version 2.37-7). Cox proportional hazards model with Breslow method for ties was used to describe the (various) age-adjusted survival curves at 1 year after ICU admission. To determine the risk factors associated with moderate to severe AKI, we conducted multivariable logistic regression. We started with a predetermined list of risk factors and fine-tuned the model until all risk factors were significant at the 0.05 level. In the process, we used Wald statistics to determine which risk factors to take out of the model and the likelihood ratio test to compare separate models.
Results
The baseline characteristics separated in four groups according to AKI-SC1UO stages are summarized in Table 2 for the 3458 critically ill patients with CLD admitted to the ICU. The overall rate of AKI was 82.5%, and the rates for stages 1, 2, and 3 were 16.7%, 40.2%, and 25.7%, respectively. Patients with stage 2-3 AKI were older, had higher APS-III scores, and had higher MELD scores. Alcohol use and nonalcoholic fatty liver disease (NAFLD) represented the most common etiologies of liver disease in patients with AKI stage 2-3. A greater proportion of patients with stage 2 and 3 AKI had sepsis and received vasopressors and/or mechanical ventilation during the first 24 hours after ICU admission.
Of the study population, 2997 (86.7%) had liver cirrhosis. Patients with cirrhosis had a significantly higher rate of AKI during the first 7 days of ICU admission when compared with patients without cirrhosis (84.6% versus 69.4%, P < 0.001).
RELATIONSHIP BETWEEN SC AND UO CRITERIA AND CLINICAL OUTCOMES IN PATIENTS WITH CLD
When either SC or UO criteria were used to define AKI, 2854 (82.5%) patients were diagnosed with AKI. AKI-SC occurred in 2002 (57.9%) patients and AKI-UO occurred in 2553 (73.8%) patients, of which 1701 also met the criteria for both AKI-SC and AKI-UO (AKI-SC1UO). Overall, there was a 1.4-fold increase Data are presented as n (%) unless noted otherwise. *Missing data: age (n 5 1); BMI (n 5 376); APS-III Score (n 5 1); severity of hypotension (n 5 44); surgical admission (n 5 162); albumin (n 5 2635); bilirubin (n 5 1082); INR (n 5 665); known baseline n 5 395); hospital admission (n 5 134); MELD score (n 5 1251); reference eGFR (n 5 1); fluids (n 5 488). † Pearson's chi-square asymptotic test for categorical variables and Kruskal-Wallis one-way analysis of variance by ranks for continuous variables. Abbreviations: ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; AKI, acute kidney injury; APS, acute physiology score; BMI, body mass index; CLD, chronic liver disease; eGFR, estimated glomerular filtration rate; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; NAFLD, nonalcoholic fatty liver disease; Q1-Q3, 1st and 3rd quartiles; SC, serum creatinine; UO, urine output.
in AKI rate when UO criteria were added to the definition compared with using SC criteria alone. The relationship between AKI stages determined by SC and UO criteria during the first week of ICU admission and the associated clinical outcomes are summarized in Table 3 . All details concerning the distribution of the patients classified by various combinations of SC and UO criteria and the relationship with hospital mortality are presented in Table 4 . When SC and UO criteria were used, 604 patients (17.5%) had no evidence of AKI and had the lowest hospital mortality rate (5%). Using UO criteria alone, 2103 patients (60.8%) were classified as AKI stage 2-3 AKI-UO, of which 1281 patients would have been classified as no AKI or stage 1 AKI-SC if only SC criteria were used. In this group, hospital mortality was 3-fold higher than that of patients without any AKI (14.6% versus 5%, P < 0.001) and more than a 50% increased mortality compared with stage 1 AKI-SC (14.6% versus 9%; P < 0.001). Conversely, 173 patients were classified as stage 2 or 3 AKI-SC but classified as no AKI or stage 1 AKI-UO. Hospital mortality was higher in this group compared with patients without any AKI (28.3% versus 5%, P < 0.001) or comparing to patients only classified as Stage 2 or 3 AKI-UO (14.6% versus 28.3%, P < 0.001).
Patients with transient oliguria (AKI-UO stage 1) had increased mortality rates compared with patients without oliguria (14.9% versus 6.9%, P < 0.001). Patients with stage 2-3 AKI were older, had higher APS-III scores, and had higher Model for End-Stage Liver Disease (MELD) score. Alcohol use and NAFLD represented the most common etiologies of liver disease in patients with AKI stage 2-3. A greater proportion of patients with stage 2 and 3 AKI had sepsis and received vasopressors and/or mechanical ventilation during the first 24 hours after ICU admission. 3 AKI-UO. Moreover, patients with no AKI-SC but with AKI-UO stage 3 (SC0-UO3) and patients with AKI-SC stage 3 but with no AKI-UO (SC3-UO0) had similar age-adjusted 1-year risk for death or RTT (data not shown).
USE OF URINARY OUTPUT CRITERIA IN PATIENTS WITH CIRRHOSIS
Among the 2997 patients with liver cirrhosis, 2387 (79.6%) had significant portal hypertension. AKI occurred during the first 7 days of ICU admission in 2051 (85.9%) patients with cirrhosis and portal hypertension compared to 483 (79.2%) patients with cirrhosis but without portal hypertension (P < 0.001). Across these groups, the association between mortality and AKI using UO criteria vs SC criteria was similar (Supporting Table S3 and S4).
RISK FACTORS OF MODERATE AND SEVERE AKI
The risk factors for moderate to severe AKI are presented in Table 5 . Patients with evidence of portal hypertension or treated for hepatic encephalopathy had increased risk for developing moderate to severe AKI compared with patients without portal hypertension or treatment for encephalopathy. Moreover, patients with CLD and hemodynamic instability requiring vasopressors also have increased risk for AKI.
Discussion
Our study examined the significance of oliguria in patients with CLD and evaluated its impact on clinical outcomes in a large cohort of patients admitted to one of eight ICUs in a large university medical center over an 8-year period. Oliguria meeting the UO criteria of AKI occurred in 73.8% of patients with CLD. Compared with AKI diagnosis using only SC criteria, incorporating oliguria into the diagnostic criteria for AKI increased the incidence of AKI from 57.9% to 82.5%. Patients classified as moderate to severe AKI were older and had higher APS-III and MELD scores. Stage 2-3 AKI was more frequent in CLD patients with cirrhosis than in those without cirrhosis, and a greater proportion had sepsis and received vasopressors and/or mechanical ventilation during the first 24 hours after ICU admission (Table 2) . Alcohol use and NAFLD represented the most common etiologies of liver disease in this group. Modeling was started with the following independent variables from Risk for death over the index hospital stay was greatest for patients that met both UO and SC criteria for AKI (AKI-SC1UO). Patients with stage 3 AKI-UO, regardless of SC, had the highest mortality rate. It was fascinating to find that the 1-year mortality rate for stage 3 AKI-UO but with normal SC was similar to patients without oliguria but with stage 3 AKI-SC. This finding underscores the importance of measuring UO in CLD patients. Our results contradicted the findings by McIlroy et al., (14) who reported that although the incidence of AKI increased when UO criteria was used, this increase was not associated with increased mortality or RRT. That study was much smaller and included cardiac surgery patients, which are different than our CLD patients. Similar findings were published by Mizota et al., (15) who reported that oliguria without SC increase had a significant negative impact on length of ICU/hospital stay and lower chronic kidney disease-free survival.
Macedo et al. (16) demonstrated that oliguric patients without a change in SC had a significantly higher mortality rate when compared with patients without AKI and are similar to oliguric patients with an increase in serum creatinine.
Different studies have produced varying estimates for the impact of the UO criteria on both AKI rate and outcomes. (14, 17) Possible explanations for the inconsistency of these results include differences in the study population and perhaps different definitions of oliguria threshold used. Some studies used modified UO criteria, for example, using 24-hour urine output to define oliguria instead of hourly urine output. (18) Interestingly, in one study of patients who developed AKI, urine output alone was a better mortality predictor than SC alone. (19) Although oliguria is potentially the earliest indication of kidney dysfunction, urine output criteria of AKI definition is frequently discarded because of difficulties in making consistent measurements. (20) A recent consensus definition by the International Ascites Club for AKI recommends the use of SC only in patients with cirrhosis because of the limitations of UO in this population. (7) In our study, transient oliguria (<12 hours) was not associated with any increase in mortality compared with no AKI when SC was not also elevated. However, in patients with stage 3 AKI-SC, the addition of even transient oliguria was associated with a dramatic increase in mortality. One third of our patients had a diagnosis of AKI due to persistent oliguria (stage 2-3 AKI-UO without or only with a slight increase of SC (stage 1 AKI-SC), and these patients had higher mortality and RRT when compared with transient oliguria (and without or only with a slight increase of SC (stage 1 AKI-SC).
Finally, our study suggests that 1) UO should be used for diagnosing and staging AKI patients with CLD and especially those with cirrhosis; 2) the severity of AKI is a strong determinant for short-and longterm outcomes in patients with CLD; 3) among patients with CLD, patients with complications of portal hypertension such as encephalopathy, varices, or ascites had the highest risk to develop AKI.
Our study has several limitations. First, our results may not be generalizable to patients outside the ICU. Second, the association between AKI and adverse long-term outcomes could be confounded by other factors that we could not measure. Third, our result should not be taken to imply that treatments to increase UO would have improved outcomes. For the purposes of our study cirrhosis was defined by ICD-9 codes for cirrhosis and associated complication. This method is known to be oversensitive. (21) Our study is retrospective and data were not recorded for the purposes of this study, limiting the strength of our conclusions. Finally, we acknowledge that the associations we have observed between AKI criteria and outcomes may be partly related to the management of these patients with differing interventions received. Because these interventions were not standardized, it is not possible to evaluate the impact of the different interventions on outcomes.
In conclusion, critically ill patients with CLD have a high rate of AKI and worse prognosis. Incorporating oliguria into the diagnostic criteria increases the measured rate of AKI. When persistent oliguria is present even without SC elevation or transient oliguria is present with SC elevation, more severe AKI is detected, and these cases have a higher risk of mortality. This finding has clear implications for early assessment and management of AKI in patients with CLD.
